TS

Todd Sone

General Partner at aMoon Fund

Israel

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

2017

  • General Partner

    2021

    Partnering with great HealthTech entrepreneurs.

  • Partner

    2017 - 2021

  • Investor & Board Observer

    2018

    Bringing the $100 genome to market.

  • Investor & Board Director

    2021

    Using biomarkers to reduce trial & error and help physicians make informed treatment decisions.

  • Investor & Board Director

    2020

    The longer the track, the greater the separation of the field.

  • Investor & Board Director

    2019

    Treating migraine (better) without drugs and without looking like a Klingon.

  • Investor & Board Director

    2019

    Designing and developing antibodies using proprietary 3D modelling.

  • Investor & Board Director

    2018

    Finding that polyp (better).

  • Investor & Board Director

    2018 - 2021

    Clinical-stage precision oncology company with a lead asset in Ph 2 trials for desmoid tumor.

  • Partner

    2009 - 2017

    Growth capital to innovative healthcare companies.

  • Investor

    2012 - 2017

    Specialty pharma focused on injectable and infusion medications. Sold to Baxter.